Cabergoline monotherapy in the long-term treatment of Cushing's disease

European Journal of Endocrinology

Volumn 163, Issue 5, 2010, Pages 709-716

  Godbout, Ariane ^a   Manavela, Marcos ^b   Danilowicz, Karina ^b   Beauregard, Hugues ^a   Bruno, Oscar Domingo ^b   Lacroix, André ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; HYDROCORTISONE; PROLACTIN; ERGOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CUSHING DISEASE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; LONG TERM CARE; LOW DRUG DOSE; MALE; MICROADENOMA; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; TIME; URINE;

ADULT; AGED; COHORT STUDIES; ERGOLINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 77957846122     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0382     Document Type: Article

References (39)

1. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A & Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2003 88 5593-5602. (doi:10.1210/jc.2003-030871) (Pubitemid 38033020)
2. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA & Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2008 93 2454-2462. (doi:10.1210/jc.2007-2734) (Pubitemid 352008503)
3. De Tommasi C, Vance ML, Okonkwo DO, Diallo A & Laws ER Jr. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome. Journal of Neurosurgery 2005 103 825-830. (doi:10.3171/jns.2005.103.5.0825) (Pubitemid 43194575)
4. Atkinson AB, Kennedy A, Wiggam MI, McCance DR & Sheridan B. Longterm remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clinical Endocrinology 2005 63 549-559. (doi:10.1111/j.1365-2265.2005.02380.x) (Pubitemid 41626751)
5. Benveniste RJ, King WA, Walsh J, Lee JS, Delman BN & Post KD. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. Journal of Neurosurgery 2005 102 1004-1012. (doi:10.3171/jns.2005.102. 6.1004) (Pubitemid 43193968)
6. Friedman RB, Oldfield EH, Nieman LK, Chrousos GP, Doppman JL, Cutler GB Jr & Loriaux DL. Repeat transsphenoidal surgery for Cushing's disease. Journal of Neurosurgery 1989 71 520-527. (doi:10.3171/jns.1989.71.4.0520)
7. Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G & Fahlbusch R. Surgical treatment of recurrent Cushing's disease. Neurosurgery 2006 58 1108-1118. (doi:10.1227/01.NEU.0000215945.26764.92) (Pubitemid 43879545)
8. Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P & Bertagna X. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 172-179. (doi:10.1210/jc.2006-1328)
9. Miller JW & Crapo L. The medical treatment of Cushing's syndrome. Endocrine Reviews 1993 14 443-458. (doi:10.1210/edrv-14-4-443)
10. Nieman LK. Medical therapy of Cushing's disease. Pituitary 2002 5 77-82. (doi:10.1023/A:1022308429992)
11. Pivonello R, Ferone D, De Herder WW, Kros JM, Del Basso De Caro MM, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ & Lamberts SWJ. Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 2452-2462. (doi:10.1210/jc.2003-030837)
12. De Bruin C, Hanson JM, Meij BP, Kooistra HS, Waaijers AM, Uitterlinden P, Lamberts SWJ & Hofland LJ. Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine Cushing's disease. Endocrinology 2008 149 4357-4366. (doi:10.1210/en.2008-0244)
13. Castillo VA, Gómez NV, Lalia JC, Cabrera Blatter MF & García JD. Cushing's disease in dogs: cabergoline treatment. Research in Veterinary Science 2007 85 26-34. (doi:10.1016/j.rvsc.2007.08.009)
14. Lamberts SW & Birkenhager JC. Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet 1976 2 811. (doi:10.1016/S0140-6736(76)90656-5)
15. Lamberts SW, Klinjn JG, De Quijada M, Timmermans HA, Uitterlinden P, De Jong FH & Birkenhager JC. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. Journal of Clinical Endocrinology and Metabolism 1980 51 307-311. (doi:10.1210/jcem-51-2-307) (Pubitemid 10007639)
16. Invitti C, De Martin M, Danesi L & Cavagnini F. Effect of injectable bromocriptine in patients with Cushing's disease. Experimental and Clinical Endocrinology and Diabetes 1995 103 266-271. (doi:10.1055/s-0029-1211361)
17. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonist and pituitary tumor shrinkage. Endocrine Reviews 1992 13 220-240. (doi:10.1210/edrv-13-2-220)
18. Mercado-Asis LB, Yasuda K, Murayama M, Mune T, Morita H & Miura K. Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinologia Japonica 1992 39 385-395.
19. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G & Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. Journal of Endocrinological Investigation 1999 22 860-865.
20. Casulari LA, Naves LA, Mello PA, Pereira Neto A & Papadia C. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Hormone Research 2004 62 300-305. (doi:10.1159/ 000082235)
21. Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, Lombardi G, Colao A, Lamberts SW & Hofland LJ. Dopamine receptor expression and function in corticotroph ectopic tumors. Journal of Clinical Endocrinology and Metabolism 2007 92 65-69. (doi:10.1210/jc.2006-0728)
22. Colao A, Di Sarno A, Pivonello R, Di Somma C & Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs 2002 11 787-800. (doi:10.1517/13543784.11.6.787) (Pubitemid 34618811)
23. Colao A, Lombardi G & Annunziato L. Cabergoline. Expert Opinion on Pharmacotherapy 2000 1 555-574. (doi:10.1517/14656566.1.3.555)
24. Manavela M, Danilowicz K & Bruno OD. Cabergoline effect in ACTH-dependent Cushing's syndrome. 12th International Congress of Endocrinology, Lisbon, Portugal, Poster-867, pp 302, August 31-September 4, 2004.
25. Miyoshi T, Otsuka F, Takeda M, Inagaki K, Suzuki J, Ogura T, Date I, Hashimoto K & Makino H. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. Journal of Endocrinological Investigation 2004 27 1055-1059.
26. Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V & Rodien P. Use of cabergoline in persisting Cushing's disease. Annales d'Endocrinologie 2006 67 353-356. (doi:10.1016/S0003-4266(06)72611-7)
27. Godbout A, Beauregard H & Lacroix A. Cabergoline in the long-term treatment of Cushing's Disease. The Endocrine Society's 89th Meeting, Toronto, Ontario, Abstract P4-51, June 2-5, 2007.
28. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD & Lacroix A. Long-term therapy with cabergoline in Cushing's disease. The Endocrine Society's 90th Meeting, San Francisco, Abstract P2-130, June 15-18, 2008.
29. Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura E, Silva L, Agra R, Pontes L, Montenegro L, Albuquerque JL & Canadas V. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 2010 13 123-129. (doi:10.1007/s11102-009-0209-8)
30. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SWJ & Colao A. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. Journal of Clinical Endocrinology and Metabolism 2009 94 223-230. (doi:10.1210/jc.2008-1533)
31. Manavela M, Danilowicz K & Bruno OD. Macrocorticotropina shrinkage and biochemical control under long-term cabergoline therapy. Proceedings European Neuroendocrine Association workshop on Novel Insights in the management of Cushing's syndrome, Napoli. Abstract 38, pp 57, December 4-6, 2009.
32. Murphy MB. Dopamine: a role in the pathogenesis and treatment of hypertension. Journal of Human Hypertension 2000 14 S47-S50. (doi:10.1038/sj.jhh.1000987)
33. Schade R, Andersohn F, Suissa S, Haverkamp W & Garbe E. Dopamine agonist and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007 356 29-38. (doi:10.1056/NEJMoa062222)
34. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonist for Parkinson's disease. New England Journal of Medicine 2007 356 39-46. (doi:10.1056/NEJMoa054830)
35. Pijl H, Ohasshi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH & DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000 23 1154-1161. (doi:10.2337/diacare.23.8.1154)
36. De Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, Van Aken MO, Van Der Lelij AJ, De Herder WW, Lamberts SW & Hofland LJ. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. Journal of Clinical Endocrinology and Metabolism 2009 94 1118-1124. (doi:10.1210/jc.2008-2101)
37. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA & Bertherat J. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 2009 94 115-122. (doi:10.1210/jc.2008-1008)
38. Boscaro M, Zhang Y, Sen K, Maldonado M, Schoenherr U & Findling J. Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a phase II extension study. The Endocrine Society's 92th meeting, San Diego, P1-274, June 19-22, 2010.
39. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ & Lamberts SW. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. New England Journal of Medicine 2010 362 1846-1848. (doi:10.1056/NEJMc1000094)